Tenet Reports Strong Third Quarter 2026 Results
TENET HEALTHCARE CORP (THC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook • Net income available to common shareholders in third quarter 2026 was $1.000 billion, or $12.41 per diluted share compared to $342 million, or $3.86 in third quarter 2025 • Adjusted dilu
How this was made
The 30-second read
Why it matters
The raised earnings and outlook provide a clear catalyst for short‑term buying interest.
Market read
Strong earnings and higher guidance make THC a near‑term bullish play.
What to watch
Potential headwinds from payer mix and upcoming RCM contract transitions could moderate future growth.
Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook
Third-quarter net operating revenues, Adjusted EBITDA, adjusted diluted earnings per share, operating cash flow and adjusted free cash flow increased year over year. Results included a $147 million favorable net impact from RCM transition activities, while the Company raised its FY 2026 Adjusted EBITDA and Adjusted Free Cash Flow outlook.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 net operating revenuesGAAP | $5.63B | – | 6.5% |
| Q3 2026 revenue from contract terminationGAAP | $646M | – | 100.0% |
| Q3 2026 equity in earnings of unconsolidated affiliatesGAAP | $64M | – | — % |
| Q3 2026 salaries, wages and benefitsGAAP | $2.17B | – | (1.4)% |
| Q3 2026 suppliesGAAP | $983M | – | 5.6% |
| Q3 2026 other operating expenses, netGAAP | $1.18B | – | 5.8% |
| Q3 2026 depreciation and amortizationGAAP | $217M | – | – |
| Q3 2026 impairment and restructuring charges, and acquisition-related costsGAAP | $37M | – | – |
| Q3 2026 litigation and investigation costs (benefit)GAAP | $6M | – | – |
| Q3 2026 net gains on sales, consolidation and deconsolidation of facilitiesGAAP | −$9M | – | – |
| Q3 2026 operating incomeGAAP | $1.75B | – | – |
| Q3 2026 operating income as a percentage of net operating revenuesGAAP | 31.1% | – | – |
| Q3 2026 interest expenseGAAP | −$203M | – | – |
| Q3 2026 other non-operating income, netGAAP | $37M | – | – |
| Q3 2026 loss from early extinguishment of debtGAAP | −$5M | – | – |
| Q3 2026 income before income taxesGAAP | $1.58B | – | – |
| Q3 2026 income tax expenseGAAP | −$360M | – | – |
| Q3 2026 net incomeGAAP | $1.22B | – | – |
| Q3 2026 net income available to noncontrolling interestsGAAP | $219M | – | – |
| Q3 2026 net income available to Tenet common shareholdersGAAP | $1B | – | – |
| Q3 2026 diluted earnings per shareGAAP | $12.41 | – | – |
| Q3 2026 basic earnings per shareGAAP | $12.48 | – | – |
| Q3 2026 Adjusted EBITDAnon-GAAP | $1.35B | – | 23.3% |
| Q3 2026 Adjusted EBITDA marginnon-GAAP | 24.1% | – | – |
| Q3 2026 adjusted net income available to common shareholdersnon-GAAP | $535M | – | – |
| Q3 2026 adjusted diluted earnings per sharenon-GAAP | $6.64 | – | 79.5% |
| Q3 2026 net cash provided by operating activitiesGAAP | $1.28B | – | – |
| Q3 2026 free cash flownon-GAAP | $1.08B | – | – |
| Q3 2026 adjusted net cash provided by operating activitiesnon-GAAP | $1.3B | – | – |
| Q3 2026 adjusted free cash flownon-GAAP | $1.10B | – | – |
| Nine months ended September 30, 2026 net operating revenuesGAAP | $16.63B | – | 5.3% |
| Nine months ended September 30, 2026 net income available to Tenet common shareholdersGAAP | $2.53B | – | – |
| Nine months ended September 30, 2026 diluted earnings per shareGAAP | $30.08 | – | – |
| Nine months ended September 30, 2026 Adjusted EBITDAnon-GAAP | $3.82B | – | – |
| Nine months ended September 30, 2026 Adjusted EBITDA marginnon-GAAP | 23.0% | – | – |
| Nine months ended September 30, 2026 adjusted diluted earnings per sharenon-GAAP | $17.50 | – | – |
| Nine months ended September 30, 2026 net cash provided by operating activitiesGAAP | $3.51B | – | – |
| Nine months ended September 30, 2026 free cash flownon-GAAP | $2.96B | – | – |
| Nine months ended September 30, 2026 adjusted free cash flownon-GAAP | $2.52B | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Ambulatory Care, Q3 2026Strong growth in consolidated same-facility net patient service revenues, acquisitions of facilities, and increased service lines. | $1.37B | – | 7.5% |
| Hospital Operations and Services, Q3 2026An increase in adjusted admissions and continued pricing strength, partially offset by unfavorable payer mix due to lower exchange admissions. Revenue included a $97 million timing-related benefit associated with the RCM Agreements. | $4.26B | – | 6.1% |
| Ambulatory Care, nine months ended September 30, 2026Adjusted EBITDA was $1,563 million and Adjusted EBITDA margin was 38.3%. | $4.08B | – | – |
| Hospital Operations and Services, nine months ended September 30, 2026Adjusted EBITDA was $2,258 million and Adjusted EBITDA margin was 18.0%. | $12.55B | – | – |
FY 2026 Outlook outlook
- Revenue$22,050 million to $22,450 million
- NoteNet income available to Tenet common shareholders: $2,973 million to $3,078 million
- NoteAdjusted EBITDA: $5,050 million to $5,200 million
- NoteAdjusted EBITDA margin: 22.9% to 23.2%
- NoteDiluted income per common share: $35.82 to $37.08
- NoteAdjusted net income: $1,830 million to $1,910 million
- NoteAdjusted diluted earnings per share: $22.05 to $23.01
- NoteEquity in earnings of unconsolidated affiliates: $265 million to $275 million
- NoteDepreciation and amortization: $865 million to $915 million
- NoteInterest expense: $815 million to $825 million
- NoteIncome tax expense: $1,135 million to $1,170 million
- NoteNet income available to NCI: $910 million to $960 million
- NoteWeighted average diluted common shares: ~83 million
- NoteNet cash provided by operating activities: $3,885 million to $4,315 million
- NoteAdjusted net cash provided by operating activities: $3,525 million to $3,925 million
- NoteCapital expenditures: $700 million to $800 million
- NoteFree cash flow: $3,185 million to $3,515 million
- NoteAdjusted free cash flow: $2,825 million to $3,125 million
- NoteNCI cash distributions: $900 million to $970 million
- NoteAmbulatory net operating revenues: $5,530 million to $5,670 million
- NoteAmbulatory Adjusted EBITDA: $2,160 million to $2,220 million
- NoteAmbulatory NCI: $865 million to $895 million
- NoteAmbulatory Adjusted EBITDA less NCI: $1,295 million to $1,325 million
- NoteAmbulatory same-facility system-wide revenues: Up 3.0% to 6.0%
- NoteHospital net operating revenues: $16,520 million to $16,780 million
- NoteHospital Adjusted EBITDA: $2,890 million to $2,980 million
- NoteHospital NCI: $45 million to $65 million
- NoteHospital inpatient admissions: Up 1.0% to 2.0%
- NoteHospital adjusted admissions: Up 1.0% to 2.0%
Capital returns
- The Company repurchased 970,000 shares of common stock for $255 million in the three months ended September 30, 2026.
- The Company repurchased 7.99 million shares of common stock for $1.615 billion in the nine months ended September 30, 2026.
- Repurchases of common stock were $1,615 million in the nine months ended September 30, 2026, compared to $1,188 million in the nine months ended September 30, 2025.
What drove it
- Consolidated Adjusted EBITDA reflected strong same-facility revenue growth and disciplined expense management.
- The Hospital segment reported adjusted admissions growth of 3.2% in Q3 2026 and same-hospital net patient service revenue per adjusted admission growth of 0.2%.
- Ambulatory same-facility system-wide net patient service revenues increased 4.5%, with net revenue per case up 6.1%, driven by higher acuity and favorable service mix.
- The RCM Agreements transition produced cumulative catch-up adjustments that increased revenue from contract termination by $233 million and net operating revenues by $97 million during Q3 2026.
- Transition activities, including efficiencies from the revised timeline, provided an approximately $50 million benefit, which together with the $97 million net operating revenue adjustment produced a $147 million favorable net impact to Q3 2026 Adjusted EBITDA.
Concerns
- Unfavorable payer mix due to lower exchange admissions partially offset consolidated and Hospital segment revenue and Adjusted EBITDA drivers.
- Ambulatory same-facility system-wide surgical cases declined 1.5% in Q3 2026, while same-business-day cases also declined 1.5%.
- Hospital surgeries declined 1.1% in Q3 2026.
- The favorable $147 million impact from transition activities was associated with the revised RCM transition timeline.
- Q3 2026 Hospital segment results included a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years.
What to watch
- Substantial completion of the transition of certain revenue cycle management services under the RCM Agreements by October 30, 2026.
- Hospital payer mix and exchange admissions.
- Ambulatory surgical-case trends and net revenue per case.
- Delivery against FY 2026 Adjusted EBITDA outlook of $5,050 million to $5,200 million and Adjusted Free Cash Flow outlook of $2,825 million to $3,125 million.
- Progress toward the FY 2026 Hospital segment adjusted admissions outlook of up 1.0% to 2.0% and Ambulatory same-facility system-wide revenue outlook of up 3.0% to 6.0%.
Balance sheet and cash flow
- Cash and cash equivalents were $2,674 million at September 30, 2026, compared to $2,883 million at December 31, 2025.
- Current portion of long-term debt was $164 million and long-term debt, net of current portion, was $13,079 million at September 30, 2026.
- Net debt to Adjusted EBITDA was 2.11x at September 30, 2026, compared to 2.33x at June 30, 2026 and 2.25x at December 31, 2025.
- In September 2026, the Company completed a private placement of $2.0 billion in aggregate principal amount of newly issued 6.250% senior notes maturing in 2034.
- The notes financed, together with cash on hand, redemption of all $1.5 billion aggregate principal amount of 5.125% senior secured first lien notes due in 2027 and partial redemption of $500 million outstanding of 6.125% senior notes due in 2028.
- Nine-month purchases of property and equipment were $(546) million, compared to $(646) million in the prior-year period.
- Nine-month purchases of businesses or joint venture interests, net of cash acquired, were $(201) million, compared to $(266) million in the prior-year period.
- Nine-month distributions paid to noncontrolling interests were $(614) million, compared to $(585) million in the prior-year period.
Analysis
Tenet reported a strong third quarter, with net operating revenues of $5,631 million versus $5,289 million and Adjusted EBITDA of $1,355 million versus $1,099 million. The Adjusted EBITDA margin was 24.1%, compared with 20.8%. GAAP net income available to common shareholders was $1,000 million, or $12.41 per diluted share, compared with $342 million, or $3.86 per diluted share. Adjusted diluted earnings per share increased 79.5% to $6.64 from $3.70.
The Hospital segment generated $4,260 million of Q3 net operating revenues, up 6.1%, and $818 million of Adjusted EBITDA, compared with $607 million. Adjusted admissions increased 3.2% and same-hospital net patient service revenue per adjusted admission increased 0.2%, but lower exchange admissions created unfavorable payer mix. The segment's results included the $147 million favorable net impact from RCM transition activities. It also recognized a $32 million favorable pre-tax impact associated with additional Medicaid supplemental revenues related to prior years.
Ambulatory Care generated $1,371 million of Q3 net operating revenues, up 7.5%, and $537 million of Adjusted EBITDA, up 9.1%. Same-facility system-wide net patient service revenues increased 4.5%, as a 6.1% increase in net revenue per case more than offset a 1.5% decline in surgical cases. Management attributed net revenue per case growth to higher acuity and favorable service mix, while citing acquisitions, increased service lines and disciplined expense management as additional segment drivers.
Cash generation remained substantial. Nine-month net cash provided by operating activities was $3,507 million versus $2,809 million, and adjusted free cash flow was $2,524 million versus $2,247 million. The Company repurchased 7.99 million shares for $1.615 billion during the nine months and reported net debt to Adjusted EBITDA of 2.11x at September 30, 2026. It also issued $2.0 billion of 6.250% senior notes maturing in 2034 and used proceeds together with cash on hand to refinance specified 2027 and 2028 notes.
The Company raised its FY 2026 outlook, including Adjusted EBITDA of $5,050 million to $5,200 million and Adjusted Free Cash Flow of $2,825 million to $3,125 million. The release states the Adjusted EBITDA midpoint increased by $195 million and the Adjusted Free Cash Flow outlook increased by $100 million. The principal operating items to follow are completion of the RCM service transition, Hospital payer mix and exchange admissions, and the ability of pricing, acuity and expense management to sustain segment margins.
Management, verbatim
Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management.
Saum Sutaria, M.D., Chairman and Chief Executive Officer
Our focus on patient-centered care, support for physician partners, technology-enabled growth and operating initiatives continue to deliver strong margins and free cash flow.
Saum Sutaria, M.D., Chairman and Chief Executive Officer
Not in the filing
stated, not guessed- Previous-release outlook was not provided, so no comparison of actual results with prior guidance is available.
- Gross margin was not reported.
- Prior-quarter comparatives were not reported for the listed financial metrics.
- A quarterly cash dividend was not reported.
- Q3 2026 cash and debt balances were not reported; the balance sheet provides September 30, 2026 balances only.
- The filing did not provide year-over-year percentage changes for several GAAP income-statement line items despite reporting their current-period and prior-year values.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Tenet Healthcare filed a Form 8‑K reporting Q3 2026 results and updated FY 2026 guidance.
Ticker impact
Tenet Healthcare reported Q3 2026 net income of $1.0B and raised FY 2026 Adjusted EBITDA outlook to $5.05‑$5.20B.
likely upward pressure as investors price in higher earnings and outlook.
Quarterly results exceed prior year and guidance was increased, indicating improved profitability and cash flow.
Market effects
Healthcare services sector may see broader optimism from Tenet's strong performance.
U.S. markets could open higher on the back of the earnings beat.
Limited to U.S. healthcare investors; no direct global ripple.
Counterpoint
If the earnings beat is already priced in, the stock could face short‑term profit taking.
Key entities
- companyTenet Healthcare Corp
U.S. healthcare services provider.
